Isatuximab combination (Isa-VRd) for Multiple Myeloma: Key Findings from the IMROZ Study

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a phase 3 clinical trial testing the monoclonal antibody isatuximab (Sarclisa, Sanofi) was presented. The IMROZ study added isatuximab to the treatment combination of bortezomib, lenalidomide, and dexamethasone, called VRd, for people with newly diagnosed multiple myeloma with 1q21+ status. 

Isatuximab’s role in multiple myeloma

Isatuximab is a CD38-targeting monoclonal antibody. CD38 is a protein found on the surface of myeloma cells, and treatments like isatuximab help slow disease progression by targeting these cells.

Isatuximab is approved in combination with other medications to treat multiple myeloma. These combinations include: 

• With pomalidomide and dexamethasone (Isa-Pd) for adults with myeloma who have received 2 therapies including lenalidomide and a proteasome inhibitor.
• With carfilzomib and dexamethasone (Isa-Kd) for adults with relapsed or refractory myeloma who have received 1 to 3 prior therapies. 
• With bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for adults with newly diagnosed myeloma who cannot be treated with a stem cell transplant. 

Watch interview with Dr. Muhamad Baljevic at the European Hematology Association conference, where he shares study insights for myeloma patients. 

New data further validates isatuximab's role in frontline myeloma therapy

The 2025 results from the IMROZ study, together with findings from this year’s IRAKLIA study, reinforce the growing role of isatuximab in the treatment of multiple myeloma, particularly for people who cannot receive a stem cell transplant. Both studies highlight not only improved treatment efficacy but also enhanced patient outcomes. 

The IMROZ trial demonstrated that adding isatuximab to the standard VRd regimen significantly improved progression-free survival and reduced the risk of disease progression or death by 40%. Importantly, more patients in the Isa-VRd group achieved MRD-negative complete remission (55.5% vs. 40.9%) and sustained MRD negativity for at least 12 months (46.8% vs. 24.3%) compared to those on VRd alone. 

The 2025 analysis went further by showing even stronger results in patients with high-risk chromosomal features such as 1q21+ abnormalities, with notably higher rates of deep and sustained response. These updates strengthen the case for isatuximab’s expanded use as part of frontline therapy myeloma patients who cannot receive a transplant. 

Takeaway message

The IMROZ study findings, highlight isatuximab’s growing impact across both relapsed and frontline treatment settings, especially for patients ineligible for stem cell transplant. 

If you're exploring your treatment options, talk to your care team about whether isatuximab could be part of your plan.

Learn more about treatment advances updates and how they may fit into your plan by visiting HealthTree News site.

READ MORE NEWS

Sources: 

• Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.